Literature DB >> 23657887

Real-time contrast-enhanced transrectal US-guided prostate biopsy: diagnostic accuracy in men with previously negative biopsy results and positive MR imaging findings.

François Cornelis1, Gérald Rigou, Yann Le Bras, Xavier Coutouly, Regis Hubrecht, Mokrane Yacoub, Gilles Pasticier, Grégoire Robert, Nicolas Grenier.   

Abstract

PURPOSE: To retrospectively evaluate diagnostic accuracy of real-time contrast material-enhanced (CE) ultrasonography (US) transrectal US-guided biopsies in patients with persistently elevated prostate-specific antigen (PSA) levels, previous negative systematic transrectal US-guided biopsy results, and positive prostate multiparametric magnetic resonance (MR) findings.
MATERIALS AND METHODS: Institutional review board approval was obtained for this retrospective study. Informed consent was waived. From 2007 to 2011, 178 patients with increased PSA levels (mean, 10.7 ng/mL [10.7 μg/L]), previous negative findings of random biopsies, and targets depicted at multiparametric MR imaging underwent transrectal US-guided prostate biopsies after injection of sulfur hexafluoride microbubbles. CE US-targeted biopsies were performed systematically in cancer-suggestive regions, followed by random acquisition of 12 nontargeted cores in all other regions. Diagnostic accuracy of CE US-targeted biopsies was measured with sensitivity, specificity, and positive and negative predictive values. Fisher exact and Mann-Whitney U tests were used to compare subgroups of patients. Potential predictive variables were examined with a logistic regression model.
RESULTS: CE US findings were positive in a first group of 158 patients and negative in a second group of 20 patients. Prostate carcinoma (PCa) was detected in 75 patients in the first group (47.5%) and in eight of the second group (40.0%). Overall cancer detection rate was 46.6% (83 of 178). In the first group, PCa was detected with targeted biopsies alone in 18 patients (24%), with nontargeted biopsies alone in 23 (30.7%), and with both in 34 (45.3%). Mean number of CE US-targeted cores per cancer-suggestive region was 2.2. CE US-targeted biopsies had a positive overall detection rate of 30.9%, while it was 6.9% for 12-core nontargeted biopsies (P < .001). PSA level and Gleason score were associated with positivity of CE US-targeted biopsies (P = .031 and P = .015, respectively).
CONCLUSION: Real-time CE US-targeted transrectal US biopsy offers excellent sensitivity for PCa detection in men with previous negative biopsy results and positive findings at multiparametric MR imaging. It may be combined with conventional random biopsies to increase specificity. © RSNA, 2013.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23657887     DOI: 10.1148/radiol.13122393

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  11 in total

1.  Diffusion-weighted MRI of the prostate: advantages of Zoomed EPI with parallel-transmit-accelerated 2D-selective excitation imaging.

Authors:  Kolja M Thierfelder; Michael K Scherr; Mike Notohamiprodjo; Jakob Weiß; Olaf Dietrich; Ullrich G Mueller-Lisse; Josef Pfeuffer; Konstantin Nikolaou; Daniel Theisen
Journal:  Eur Radiol       Date:  2014-08-27       Impact factor: 5.315

Review 2.  Advances in Imaging in Prostate and Bladder Cancer.

Authors:  Abhishek Srivastava; Laura M Douglass; Victoria Chernyak; Kara L Watts
Journal:  Curr Urol Rep       Date:  2017-09       Impact factor: 3.092

3.  A direct comparison of contrast-enhanced ultrasound and dynamic contrast-enhanced magnetic resonance imaging for prostate cancer detection and prediction of aggressiveness.

Authors:  Alexander D J Baur; Julia Schwabe; Julian Rogasch; Andreas Maxeiner; Tobias Penzkofer; Carsten Stephan; Marc Rudl; Bernd Hamm; Ernst-Michael Jung; Thom Fischer
Journal:  Eur Radiol       Date:  2017-12-13       Impact factor: 5.315

4.  Evidence-based guideline recommendations on multiparametric magnetic resonance imaging in the diagnosis of prostate cancer: A Cancer Care Ontario clinical practice guideline.

Authors:  Masoom A Haider; Xiaomei Yao; Andrew Loblaw; Antonio Finelli
Journal:  Can Urol Assoc J       Date:  2017-01-12       Impact factor: 1.862

5.  Bursting Microbubbles: How Nanobubble Contrast Agents Can Enable the Future of Medical Ultrasound Molecular Imaging and Image-Guided Therapy.

Authors:  Agata A Exner; Michael C Kolios
Journal:  Curr Opin Colloid Interface Sci       Date:  2021-05-02       Impact factor: 8.209

6.  Urovision 2020: The future of urology.

Authors:  Vivek Venkatramani
Journal:  Indian J Urol       Date:  2015 Apr-Jun

7.  Repeat Targeted Prostate Biopsy under Guidance of Multiparametric MRI-Correlated Real-Time Contrast-Enhanced Ultrasound for Patients with Previous Negative Biopsy and Elevated Prostate-Specific Antigen: A Prospective Study.

Authors:  Dong Ryul Jang; Dae Chul Jung; Young Taik Oh; Songmi Noh; Kyunghwa Han; Kiwook Kim; Koon-Ho Rha; Young Deuk Choi; Sung Joon Hong
Journal:  PLoS One       Date:  2015-06-17       Impact factor: 3.240

8.  The role of imaging in the diagnosis of primary prostate cancer.

Authors:  Hugh Harvey; Nandita M deSouza
Journal:  J Clin Urol       Date:  2016-12-01

9.  Medical imaging in personalised medicine: a white paper of the research committee of the European Society of Radiology (ESR).

Authors: 
Journal:  Insights Imaging       Date:  2015-03-13

10.  In vivo imaging of prostate cancer using an anti-PSMA scFv fragment as a probe.

Authors:  Claire Mazzocco; Giulio Fracasso; Coralie Germain-Genevois; Nathalie Dugot-Senant; Mariangela Figini; Marco Colombatti; Nicolas Grenier; Franck Couillaud
Journal:  Sci Rep       Date:  2016-03-21       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.